Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplontersen Open-Label Extension in ATTR-CM
NCT05667493Phase 3Enrolling by invitation
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Aug 2029
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), sponsored by Ionis Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) at 36 months, Change From Baseline in Platelet Count at 36 months and 2 more. Started Nov 2022; status: enrolling by invitation.
02
Drugs
eplontersen
03
Conditions
transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT05667493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667493.